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The CD70-CD27 interaction is known to positively regulate T cell expansion and effector function by pro-
viding costimulatory signals. In this issue of Immunity, Coquet et al. (2013) show an unexpected T-helper-
17-cell-specific negative regulation mediated by CD70-CD27 interaction.It is well established that the functional
differentiation of CD4+ T helper (Th) cells
requires three kinds of signals: those of
costimulation, the T cell receptor (TCR),
and cytokines. Costimulation determines
the activation, proliferation, and survival
of T cells, thereby generally supporting
the differentiation and effector function of
Th cells (Nurieva et al., 2011). On the other
hand, the fate decision of Th-cell-lineage
differentiation is largely determined by
the third signal—the local cytokine milieu
provided by antigen-presenting cells
(APCs). For example, interleukin-12 (IL-
12) induces Th1 cells and IL-4 induces
Th2 cells, whereas IL-6, together with
transforming growth factor b (TGF-b),
potently induces Th17 cell differentiation.
Under certain conditions, the strength
of TCR signaling and different types of
costimulations can also modulate Th cell
polarization through T-cell-intrinsic mech-
anisms. For example, the inducible costi-
mulator ICOS positively regulates the
differentiation or expansion of Th2, Th17,
and T follicular helper (Tfh) cells (Nurieva
et al., 2011). In this issue of Immunity,
Coquet et al. (2013) show that the so-
called CD70-CD27 costimulatory path-
way can also exert an inhibitory effect
by selectively suppressing the migration
and effector gene expression of Th17
cells.
CD27 belongs to the tumor-necrosis-
factor-receptor superfamily of costimula-
tors and is constitutively expressed on
CD4+ and CD8+ T cells, which can be
further upregulated after antigenic stimu-
lation. CD70, the ligand for CD27, is tran-
siently expressed on activated dendritic
cells (DCs), B cells, and T cells. CD70-
CD27 signaling facilitates the proliferation
and survival of activated T and B cells and
thereby positively regulates their effectorfunction and memory responses and
prevents tolerance induction (Nolte
et al., 2009). Previous studies have sug-
gested that CD70-CD27 interaction
might also regulate the polarization of
CD4+ T cells. For example, anti-CD70
treatment was able to suppress Th17-
cell-mediated inflammatory diseases,
including experimental autoimmune
encephalomyelitis (EAE), and CD70-
transgenic mice showed increased inter-
feron-g-producing CD4+ and CD8+
T cells (Nolte et al., 2009). These data
suggest a positive role of CD70-CD27
interaction in regulating Th1 and Th17
cells. However, the negative correlation
between CD27 and IL-17 production in
gd T cells indicates that CD27 signaling
might actually inhibit IL-17 expression
(Ribot et al., 2009), which was further
demonstrated in a Th17-cell-differentia-
tion culture (Libregts et al., 2011). More-
over, the effect of CD70-CD27 signaling
on Th1 cell differentiation might depend
on genetic background or experimental
conditions (Libregts et al., 2011). Consid-
ering the discrepancy among these
studies and the complicated role of
CD70-CD27 signaling in the immune
system, whether CD70-CD27 costimula-
tion can directly instruct Th cell polariza-
tion other than the general costimulatory
effect remains unclear.
To clarify the function of CD70-CD27
costimulation in Th cell polarization,
especially in Th17 cells, the authors
took advantages of several gain-of-func-
tion or loss-of-function approaches, in-
cluding the use of Cd27/, Cd70cre/cre
(i.e., Cd70/), and Cd70 transgenic (tg)
mice (CD70 is constitutively expressed
on conventional DCs under the control
of theCd11c promoter). In the EAEmodel,
the authors found that, compared withImmunitywild-type (WT) mice, both CD27- and
CD70-deficient mice showed significantly
exacerbated disease, as well as in-
creased mortality. In contrast, Cd70tg
mice showed alleviated disease symp-
toms. Accordingly, the authors observed
increased myelin-oligodendrocyte-glyo-
coprotein-specific Th17 cells in Cd27/
mice and a decrease in Cd70tg mice in
the EAE model. The similar phenotypes
between Cd27/ and Cd70/ mice
and the opposite phenotype in Cd70tg
mice provide strong evidence that CD70
indeed signals through CD27 to control
Th17 cell responses in vivo, either directly
or indirectly. For determining whether
this is due to a T-cell-intrinsic effect via
CD70-CD27 signaling, an adoptive T-
cell-transfer EAE model using Cd27/
CD4+ T cells and Cd70/ recipient mice
will be useful.
To further characterize the role of
CD70-CD27 signaling in Th17 cell differ-
entiation in vitro, the authors adopted a
coculture system by using purified WT
and Cd27/ naive CD4+ T cells in the
presence of irradiated WT splenocytes
and polarizing cytokines. Th17 cell differ-
entiation was normal in both WT and
Cd27/ cells. However, the addition
of a CD70 mimicry protein (FcCD70)
greatly reduced the frequency of IL-17-
producing cells in WT, but not Cd27/,
cultures. The findings were also con-
firmed in Th17 cell differentiation per-
formed with an APC-free culture system.
It was shown that CD70-CD27 signaling
can increase IL-2 expression, thereby
inhibiting IL-17 through the antagonistic
function between the transcription factors
STAT3 and STAT5 (Nolte et al., 2009).
To exclude this possibility, the authors
blocked IL-2R in their culture, yet























Figure 1. Role of CD70-CD27 Signaling in the Control of Th17 Cell Differentiation
CD70 is induced in activated DCs and signals through CD27 on activated CD4+ T cells, leading to
enhanced phosphorylation of JNK via TRAF2 or TRAF5 signaling. Activation of JNK antagonizes
RORgt-induced IL-17, IL-17F, and CCR6 expression via transcriptional suppression or through epigenet-
ically silencing the Il17a locus; this then limits overactivation of Th17-cell-mediated responses and asso-
ciated autoimmunity andmight help to maintain homeostasis of the gut-associated immune system (Nolte
et al., 2009).
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differentiation even when it was added
48 hr later, after T cell activation. These
results, together with EAE experiments,
demonstrate a direct inhibitory role of
CD70-CD27 signaling in Th17 cell differ-
entiation independently of the general
effect of costimulation on T cell prolifera-
tion and survival.
To ascertain the underlying mechanism
of how CD70-CD27 signaling controls
Th17 cell differentiation, the authors ex-
tensively examined the expression of
a number of genes associated with Th17
cells and other Th cell lineages. Surpris-
ingly, CD27 signaling only reduced the
amount of IL-17, IL-17F, and the chemo-
kine receptor CCR6, but not any other
proteins crucial for Th17 cell develop-
ment, including RORs, Batf, and IL-23R.
Inhibition of the chemokine receptor
CCR6 by CD27 costimulation was also
confirmed in their Cd70tg EAE model.
These data showed that CD70-CD27
signaling selectively regulates Th17 cells
by controlling both their migration and
their effector function, but not the general
or early stage of Th17-cell-polarization2 Immunity 38, January 24, 2013 ª2013 Elsevprogramming. This is in contrast to the
function of ICOSL-ICOS costimulation in
Th17 cell and Tfh cell differentiation.
Further investigation showed that CD27
signaling inhibited Th17 cells by en-
hancing the level of phospho-Jun amino-
terminal kinase (JNK) given that a JNK
inhibitor was able to rescue the inhibitory
effect of CD27 costimulation on Th17
cells. Additionally, CD27 costimulation in-
creased the amount of the nonpermissive
histone marker H3K27me3 at the IL-17
gene locus, and treatment with DNA-
demethylating agent 5-azacytidine signif-
icantly restored IL-17 production in CD27-
stimulated Th17 cells, suggesting that
CD70-CD27 signaling controls IL-17 ex-
pression in Th17 cells both transcrip-
tionally and epigenetically.
It is noted that previous studies
showed that CD70-blocking antibody
prevented EAE in SJL/J mice (Nakajima
et al., 2000) and that overexpression of
CD70 in B cells enhanced EAE in 2D2
mice (Francosalinas et al., 2012), which
is in contrast to Coquet et al. (2013)
finding that overexpression of CD70 in
DCs reduced EAE but that deficiency ofier Inc.CD70 and CD27 led to enhanced EAE.
Moreover, Coquet et al. (2013) showed
that CD70-CD27 signaling did not affect
Th1 differentiation on the basis of their
EAE experiments using Cd70-transgenic
and Cd27/mice and in vitro differentia-
tion assay using Cd27/ T cells, sug-
gesting a Th17-specific role of CD70-
CD27 interaction. However, this finding
is also opposite to the result obtained
with transgenic mice with CD70 overex-
pression in B cells (Arens et al., 2001).
These inconsistencies might have been
caused by the general effect of CD70-
CD27 interaction on T and B cell activa-
tion given that constitutive overex-
pression of CD70 in B cells disrupts
the homeostasis of the normal immune
system and thus leads to T cell hyper-
activation and gradual B cell depletion
(Tesselaar et al., 2003). For distinguishing
the general costimulatory function and its
inhibitory effect on Th17 cells, a careful
examination of T cell transfer with the
use of Th17- and Th1-biased disease
models would be useful. CD70-CD27
costimulation can activate many dif-
ferent signaling pathways, including those
of canonical-alternative NF-kB, mitogen-
activated protein kinase, and JNK (Nolte
et al., 2009). Coquet et al. (2013) showed
that CD70-CD27 signaling inhibited Th17
cells by selectively enhancing JNK activa-
tion. It is therefore worth identifying the
downstream JNK target(s) that directly
control(s) the expression of IL-17 and
CCR6 in Th17 cells, as well as examining
whether CD70-CD27 interaction uses a
distinct mechanism in negative regulation
of Th17 cells and its other immune-related
functions. Interestingly, a subset of APCs
has been shown to express CD70 con-
stitutively in the lamina propria, where
plenty of Th17 cells are generated at
steady phase (Atarashi et al., 2008). How-
ever, these cells were shown to be able to
induce Th17 differentiation through the
bystander effect of secreting IL-6 and
IL-23 in the presence of ATP ormicrobiota
(Atarashi et al., 2008). It would still be
interesting to know whether these intes-
tinal CD70+ APCs can also restrain
excessive Th17 gene expression via
directly signaling through CD27 and
thereby maintain the balance of gut-
associated mucous immune homeo-
stasis. Importantly, considering the varied
results achieved in different mouse
models and experimental conditions
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CD27 signaling obtained in the mouse
system, including its effect on Th17 cell
differentiation, need to be reexamined
and validated in the human immune
system. These additional studies would
be important for completely clarifying the
specificity of the CD70-CD27 axis in regu-
lating Th17 cells and laying basis for
developing therapeutics against Th17-
related inflammatory and autoimmune
diseases. Despite those remaining issues,
the study by Coquet et al. (2013) in
this issue of Immunity provides com-
pelling in vitro and in vivo experimental
evidence to support a T-cell-intrinsic role
of CD70-CD27 interaction in inhibiting
Th17 cell differentiation and migration,
adding a new brake to prevent a train
wreck of Th17-cell-mediated immunityand possibly to secure the homeostasis
of the gut-associated immune system
(Figure 1).REFERENCES
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In this issue of Immunity, studies by Blanc et al. (2013) and Liu et al. (2013) reveal how interferon induction of
cholesterol-25-hydroxylase mediates innate immunity against multiple diverse viruses.Virus infection and immune cell activation,
respectively, induce production of type I
and type II interferons (IFNs). The IFNs
are secreted and engage receptors on
cells to induce JAK-STAT signaling
pathways that activate STAT1 and
promote interferon-stimulated gene (ISG)
expression. ISG products mediate
effector actions that restrict virus infection
and modulate the immune response.
However, IFN actions are complex
and connected to the regulation of cellular
metabolic processes whose alteration
works cooperatively or even synergisti-
cally with IFNs to control infection.
Blanc et al. recently identified the regula-
tion of sterol biosynthesis as an IFN-medi-
ated antiviral strategy (Blanc et al.,
2011). This IFN-sterol crosstalk is
mediated through cholesterol-25-hydrox-
ylase (Ch25h), an ISG product thatoxidizes cholesterol to the soluble oxy-
sterol metabolite, 25-hydroxycholesterol
(25HC) (Park and Scott, 2010). 25HC has
important effects relating to lipid biosyn-
thesis and immunity. 25HC suppresses
sterol regulatory element binding protein
(SREBP)-2, a transcription factor regu-
lating the sterol biosynthesis pathway
and lipid metabolism (Brown and Gold-
stein, 1999). Additionally, activation of
Liver X receptor (LXR) by oxysterols
including 25HC modulates cholesterol
homeostasis (Ma et al., 2008). Finally,
25HC suppresses mevalonate to block
sterol biosynthesis and the production of
the prenyl lipids, farnesyl and geranylger-
anyl (Ye et al., 2003). A notable example of
mevalonate suppression in an antiviral
response is that of hepatitis C virus,
where loss of geranylgeranylation of host
proteins leads to restriction of viral repli-cation when mevalonate is limiting (Ye
et al., 2003). Moreover, these functions
of 25HC have additional effects on regula-
tion of adaptive immunity, thus under-
scoring a pivotal role for 25HC production
in antiviral immunity (Bauman et al., 2009;
Hannedouche et al., 2011).
In this issue of Immunity, Blanc et al.
(2013) assessed the connection between
IFN-mediated antiviral immunity and oxy-
sterols. The research team quantitated
the production of all known naturally
occurring oxysterols from macrophages.
They identified 25HC as the only oxysterol
produced in response to type I or type II
interferon treatment or during murine
cytomegalovirus (MCMV) infection. The
production of 25HCwas found to be regu-
lated through IFN signaling and medi-
ated by STAT1 binding to the Ch25h
promoter. Moreover, 25HC treatment of38, January 24, 2013 ª2013 Elsevier Inc. 3
